Homeopathic treatment of multiple cysts in ovary

An open observational clinical study of individualized homoeopathic treatment in polycystic ovarian syndrome (PCOS) and validation of the Bengali version of modified polycystic ovarian syndrome questionnaire (MPCOSQ)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/04/013367

Enrollment

100

Registered

2018-04-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Polycystic Ovarian Syndrome (PCOS)

Interventions

Intervention1: Indicated homoeopathic medicines in centesimal or fifty millesimal potencies: Indicated homoeopathic medicines in centesimal or fifty millesimal potencies, as decided appropriate to the

dosage and repetition depending upon the individual requirement of the cases. In 50 millesimal scale, a single medicated cane sugar globules of poppy seed size (no. 10) shall be dissolved in 90 ml dis

16 doses to be marked on the vial

each dose of 5 ml to be taken after 10 uniformly forceful downward strokes to the vial in 45 ml normal water in a clean cup, to stir well, to take 5 ml of this liquid orally, and to discard rest of th

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed PCOS as per Rotterdam diagnostic criteria [23] (developed in 2003 to aid clinicians in the systematic and accurate diagnosis of PCOS). It states that two of the following three criteria should be present for a diagnosis: a) oligo-ovulation or anovulation; b) clinical and/or biochemical signs of hyperandrogenism; and c) polycystic ovaries. Furthermore, the likelihood of other similar illnesses (such as Cushingâ??s syndrome) should first be systematically excluded. New criteria have recently been proposed by the Androgen Excess and PCOS Society, which suggest tighter definitions are required by focusing on only two criteria: a) hyperandrogenism (clinical hirsutism or biochemical hyperandrogenaemia, or both); and b) ovarian dysfunction (oligo-ovulation or anovulation, or polycystic ovaries, or both). 2. Age 18-45 years 3. Symptomatic for at least last 3 months 4. Patients taking oral contraceptive pills (OCPs) will be advised to stop pills till it exhaust for the ongoing cycle, followed by re-assessment of symptoms in the next cycle enrolment 5. Patients under hormonal replacement therapy (HRT) to be included after a washout period of 3 months 6. Patients with known but controlled systemic diseases with medication 7. Ability to read Bengali 8. Patients giving written consent to participate

Exclusion criteria

Exclusion criteria: 1. Unevaluated gynaecological abnormalities; e.g. unexplained vaginal bleeding, cervical dysplasia, pelvic inflammatory diseases (PID) within one month, patients with suspicious adenomyosis, gross developmental defect or congenital abnormalities of the uterus etc. 2. Genito-urinary tract malignancy 3. Patients desiring immediate surgical management for PCOS 4. Patients insisting to use OCPs 5. Patients with psychiatric diseases 6. Pregnancy and lactation 7. Cases suffering from uncontrolled systemic illness or life-threatening infections or any vital organ failure 8. Cases already undergoing homoeopathic treatment for any chronic disease 9. Substance abuse and/or dependence 10. Self-reported immune-compromised state

Design outcomes

Primary

Measure	Time frame
Pelvic/transvaginal ultrasound and blood LH:FSH levelTimepoint: Baseline and after 6 months	—

Secondary

Measure	Time frame
EQ-5D-5L questionnaire; validated Bengali versionTimepoint: Baseline, after 3 and 6 months;Modified PCOS questionnaire (MPCOSQ); translated Bengali versionTimepoint: Baseline, after 3 and 6 months	—

Countries

India

Contacts

Public ContactSubhranil Saha

National Institute of Homoeopathy, Ministry of AYUSH, Govt. of India

drsubhranilsaha@hotmail.com9831063837

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026